Surgery Partners outlook, USPI leadership move & more – 5 recent key notes on ASC companies
The $792 million Surgery Partners and Symbion deal is expected to close in the fourth quarter of this year. Moody's Investors Services gave Surgery Partners a 'B3' rating. Moody's attributed its rating to the company's high level of debt, but offered a positive outlook on the company's place in a growing industry. Standard & Poor's Ratings Service predicts moderate cash flow and stable margins, but mentioned the risk of integration on such a large scale.
In the closing of the $2.35 billion Sheridan Healthcare acquisition, AmSurg paid approximately $2.1 billion in cash and issued 5.7 million shares of common stock.
Harold L. Paz, MD, a United Surgical Partners International board member, will join Aetna as executive vice president and chief medical officer.
Hospital Corporation of America stock traded at $62.44 per share during the week of July 14 to 18, up 11.62 percent.
Medical Facilities Corporation announced a cash pay dividend of $Cdn$0.09375 per common share, while will be payable on August 15.
If you have a question, issue or note to suggest on an ASC management and development company please contact Carrie Pallardy at firstname.lastname@example.org or Laura Dyrda at email@example.com.
More Articles on ASC Issues:
9 ASC Joint Venture Operating Agreement Issues That Make or Break the Partnership
6 Recent GI Field Partnerships
6 Must-Reads for ASC Turnaround Success
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- Republicans pull AHCA: 7 key notes
- The out-of-network co-pay conundrum – To waive or not to waive ... And how?
- Mobile apps equally effective as in-person visit following ambulatory surgery: 4 things to know
- Ambulatory services market to increase at 6% CAGR through 2024: 5 notes
- Dr. Cheryl Pegus: 5 strategies to becoming a physician leader